Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Shares Outstanding (2016 - 2025)

Karyopharm Therapeutics' Shares Outstanding history spans 13 years, with the latest figure at $18.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 117.65% year-over-year to $18.3 million; the TTM value through Dec 2025 reached $18.3 million, up 117.65%, while the annual FY2025 figure was $18.3 million, 117.65% up from the prior year.
  • Shares Outstanding reached $18.3 million in Q4 2025 per KPTI's latest filing, up from $8.7 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $114.5 million in Q3 2023 to a low of $7.5 million in Q4 2022.
  • Average Shares Outstanding over 5 years is $48.8 million, with a median of $46.7 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding: crashed 93.19% in 2024, then skyrocketed 117.65% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $75.7 million in 2021, then crashed by 90.04% to $7.5 million in 2022, then rose by 1.5% to $7.7 million in 2023, then rose by 9.82% to $8.4 million in 2024, then surged by 117.65% to $18.3 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Shares Outstanding are $18.3 million (Q4 2025), $8.7 million (Q3 2025), and $8.6 million (Q2 2025).